<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04917250</url>
  </required_header>
  <id_info>
    <org_study_id>TRhos-ENKTCL-7</org_study_id>
    <nct_id>NCT04917250</nct_id>
  </id_info>
  <brief_title>GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma</brief_title>
  <official_title>Gemcitabine, Pegaspargase, Etoposide, and Dexamethasone (GPED) for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of GPED (gemcitabine,&#xD;
      pegaspargase, etoposide, and dexamethasone) regimen in the treatment of Relapsed/Refractory&#xD;
      or advanced NK/T-cell lymphoma patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>24 weeks ±7 days</time_frame>
    <description>evaluated by PET-CT and MRI, according to Lugano 2014 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete response rate</measure>
    <time_frame>24 weeks ±7 days</time_frame>
    <description>evaluated by PET-CT and MRI, according to Lugano 2014 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year progression free survival rate</measure>
    <time_frame>up to 1year after enrollment</time_frame>
    <description>time from date of enrollment to date of disease progression, death of any reason, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival rate</measure>
    <time_frame>up to 1year after enrollment</time_frame>
    <description>time from date of enrollment to date death of any reason</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Extranodal NK/T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with gemcitabine, pegaspargase, etoposide and dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000mg/㎡，d1,4 ivdrip</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegaspargase</intervention_name>
    <description>2500IU/㎡, maximum dose less than 3750IU</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>100mg/㎡，d1-3 ivdrip</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20mg/d d1-4 ivdrip</description>
    <arm_group_label>treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Histopathology and immunohistochemistry confirmed diagnosis of NK/Tcell lymphoma according&#xD;
        to WHO 2016 criteria.&#xD;
&#xD;
          -  refractory or relapsed after initial remission, or stage III-IV de novo patients&#xD;
&#xD;
          -  PET/CT or CT/MRI with at least one objectively evaluable lesion.&#xD;
&#xD;
          -  General status ECOG score 0-3 points.&#xD;
&#xD;
          -  The laboratory test within 1 week before enrollment meets the following conditions:&#xD;
             Blood routine: Hb&gt;80g/L, PLT&gt;50×10e9/L. Liver function: ALT, AST, TBIL ≤2 times the&#xD;
             upper limit of normal. Renal function: Cr is normal. Cardiac function: LVEF≥50%, ECG&#xD;
             does not suggest any acute myocardial infarction, arrhythmia or atrioventricular&#xD;
             conduction above I Blocking.&#xD;
&#xD;
          -  Sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Active infection requires ICU treatment. Concomitant HIV infection or active infection with&#xD;
        HBV, HCV. Patients who are infected with HBV but not active hepatitis at the same time are&#xD;
        notexcluded.&#xD;
&#xD;
        Significant organ dysfunction Pregnant and lactating women. Had a history of autoimmune&#xD;
        diseases, and disease was active in the last 6 months.&#xD;
&#xD;
        Those who were known to be allergic to drugs in the study regimen. Patients with other&#xD;
        tumors who require surgery or chemotherapy within 6 months.&#xD;
&#xD;
        • Other experimental drugs are being used.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liang Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liang Wang, M.D.</last_name>
    <phone>+861058268442</phone>
    <email>wangliangtrhos@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Wang, M.D.</last_name>
      <phone>+861058268442</phone>
      <email>wangliangtrhos@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 2, 2021</last_update_submitted>
  <last_update_submitted_qc>June 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tongren Hospital</investigator_affiliation>
    <investigator_full_name>LIANG WANG</investigator_full_name>
    <investigator_title>Director of Dept. of Hematology, Beijing Tongren Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

